SCHEMBL6320830

SCHEMBL6320830

CN[C@H](Cc1cccc2ccccc12)C(=O)N(C)[C@H](Cc1ccccc1)C(=O)NCC1CCCO1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.44
HTR2A P28223 10/20 0.44
KDM4E B2RXH2 4/20 0.44
CYP3A4 P08684 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 3/20 0.44
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
DRD1 P21728 1/20 0.44
SLC6A4 P31645 1/20 0.44
OPRM1 P35372 1/20 0.44
DRD3 P35462 1/20 0.44
KCNH2 Q12809 1/20 0.44
CYP2D6 P10635 1/20 0.44
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8710834 1.00 CYP1A2 (0.44) CYP1A2HTR2AKDM4ECYP3A4MEN1
SCHEMBL6319182 0.89 CYP1A2 (0.45) CYP1A2HTR2AKDM4ECYP3A4MEN1
SCHEMBL8906161 0.86 CYP1A2 (0.45) CYP1A2KDM4ECYP3A4KMT2AALDH1A1
SCHEMBL6319439 0.86 CYP1A2 (0.45) CYP1A2KDM4ECYP3A4KMT2AALDH1A1
SCHEMBL6319467 0.85 HTR2A (0.43) CYP1A2HTR2AKDM4ECYP3A4MEN1
SCHEMBL8906581 0.81 HTR2A (0.40) CYP1A2HTR2AKDM4ECYP3A4MEN1
SCHEMBL6318585 0.81 HRH4 (0.50) MEN1KMT2A
SCHEMBL6319828 0.81 GHSR (0.44) HTR2AKDM4ECYP3A4MEN1KMT2A
SCHEMBL6325980 0.81 GHSR (0.44) HTR2AKDM4ECYP3A4MEN1KMT2A
SCHEMBL6325987 0.81 GHSR (0.44) HTR2AKDM4ECYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 CYP1A2 2262/4885HTR2A 494/4885KDM4E 2754/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR CYP1A2 2425/4885HTR2A 533/4885KDM4E 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.